Background:
This study aimed to investigate the effects of guluronic acid (G2013) on blood
sugar, insulin, and gene expression profile of oxLDL receptors (SR-A, CD36, LOX-1, and CD68) in
the experimental model of diabetes.
Methods:
18 Sprague Dawley rats were randomly assigned to three groups of healthy control, diabetic
control, and G2013 group. Diabetes was induced through intraperitoneal (IP) injection of 60 mg/kg
streptozotocin. The subjects were IP treated with 25 mg/kg of G2013 per day for 28 days. The body
weight, food intake, fasting blood glucose and insulin were measured. In addition, the expression of
mentioned genes was investigated through quantitative real-time PCR.
Results:
The data showed that the final weight increased significantly in the G2013-treated subjects
compared to the diabetic control (p < 0.05). The results indicated that final food intake significantly
reduced in the G2013-treated subjects compared to the diabetic control (p < 0.05). The study findings
also suggested that the final fasting blood glucose significantly reduced in the G2013-treated group,
whereas the final fasting serum insulin level significantly increased in this group compared to the diabetic
control (p < 0.05). Moreover, the gene expression levels of SR-A, CD36, LOX-1, and CD68 in
the G2013 group significantly reduced compared to the diabetic control (p < 0.05).
Conclusion:
This study showed that G2013, could reduce blood glucose and increase insulin levels
and reduce the gene expression level of oxLDL receptors. In addition, it may probably play an important
role in reducing the severity of diabetes-induced inflammatory symptoms.
Regulating Hypothalamus Gene Expression in Food Intake: Dietary Composition or Calorie Density?
